Singapore, May 12 -- Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has successfully manufactured a novel viral vector gene therapy with itsAAV Curator(R) Platformto treat a baby with the ultra-rare disease Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures (NEDAMSS). This is a major accomplishment as the therapy was produced and released only 10 months from the start of development and 14 months after the patient's initial diagnosis. This feat establishes yet another foothold for gene therapies as an effective and accessible treatment for patients.

NEDAMSS is a neurodegenerative disease affecting the cen...